(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/022838 A8

(51) International Patent Classification:
C07J 9/00 (2006.01) *A61P 1/16* (2006.01)
A61K 31/575 (2006.01)

(21) International Application Number:
PCT/CA2010/001338

(22) International Filing Date:
25 August 2010 (25.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/236,750 25 August 2009 (25.08.2009) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 61/064,280 (CIP)
Filed on 26 February 2008 (26.02.2008)

(71) Applicant *(for all designated States except US)*: **BRITISH COLUMBIA CANCER AGENCY BRANCH** [CA/CA]; 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LING, Victor** [CA/CA]; 5671 Trafalgar Street, Vancouver, British Columbia V6N 1C2 (CA). **WANG, Renxue** [CA/CA]; 6210 Logan Lane, Vancouver, British Columbia V6T 2K9 (CA). **SHEPS, Jonathan Ahab** [CA/CA]; 217-518 Moberly Road, Vancouver, British Columbia V5Z 4G3 (CA).

(74) Agents: **CHATTERJEE, Alakananda, Ph.D.** et al.; Gowling Lafleur Henderson LLP, P.O. Box 30, Suite 2300, 550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
16 June 2011

(15) Information about Correction:
see Notice of 16 June 2011

(54) Title: POLYHYDROXYLATED BILE ACIDS FOR TREATMENT OF BILIARY DISORDERS

(57) Abstract: The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertesion. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow. New compounds 2α,3α,7α,12α-tetrahydroxy-5β-cholanoic acid and 3α,4α,7α,12α-tetrahydroxy-5β-cholanoic acid are disclosed, uses thereof and synthesis thereof.

WO 2011/022838 A8